Evaluation agreement signed with Gulf Drug LLC regarding potential distribution in the UAE

Hemcheck Sweden AB has signed a 5-month evaluation agreement with potential continuation into a 25-month long distribution agreement with Gulf Drug LLC (”Gulf Drug”), one of the leading distributors of medical equipment in the UAE. The agreement is formed to evaluate the collaboration and market opportunity, and will be exclusive for the UAE market, should the evaluation be successful according to both parties. Gulf Drug has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR, should the agreement be extended after the 5-month evaluation period.

– Gulf Drug is a large and well-established distributor in the UAE, with a profile that fits Hemcheck very well. We look forward to working with Gulf Drug and hope that the collaboration will be long term and that the evaluation period will be successful, says Joen Averstad, CEO of Hemcheck.

– We are very satisfied that we have signed an evaluation agreement with Hemcheck, and we will start the evaluation as soon as we can. We think the products have good market potential and we look forward to the collaboration, says Dr Samir Al Hossary, Director at Gulf Drug.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Gulf Drug LLC

Gulf Drug LLC was founded in 1969 with its head office located in Dubai. It’s one of the leading distributors of medical and laboratory equipment in the UAE. Gulf Drug is a partner to global manufacturers such as Abbott, Hemocue, and Randox.

Read more at: https://www.gulfdrug.com/ 

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.